Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics for Gut Microbiota Knockdown in Obesity and Insulin Resistance
NCT02241421Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2012
- Primary completion
- Oct 2014
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in obesity and insulin resistance (IR) comparing Placebo, Amoxicillin and Vancomycin (3 arms). Primary endpoint: Insulin sensitivity up to 2 weeks. Started Apr 2012; status: completed.
02
Drugs
amoxicillinvancomycin
03
Conditions
obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT02241421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241421.